Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Berchuck

Showing results (451-460 of 683) with videos related to

Pageof 69
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 29, 2020
Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinomaKathryn Lasseter, Amin H Nassar, Lana Hamieh, et al.
Journal of Women'S Health (2002)|February 18, 2016
The Association Between Body Mass Index and Presenting Symptoms in African American Women with Ovarian CancerChioma O Erondu, Anthony J Alberg, Elisa V Bandera, et al.
Molecular Carcinogenesis|April 12, 2011
Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer riskEllen L Goode, Kristin L White, Robert A Vierkant, et al.
Nature Genetics|April 26, 2022
HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancerXiaodong Lu, Ka-Wing Fong, Galina Gritsina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcomeAndrew Berchuck, Edwin S Iversen, Jingqin Luo, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
A chromatin fiber model explains cell-free DNA fragmentation signatures of active regulatory elementsAlexis Yang, Garyoung Gary Lee, Surya Chhetri, et al.
Gynecologic Oncology|April 17, 2019
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapiesStéphanie L Gaillard, Kaitlyn J Andreano, Laurie M Gay, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignanciesA M Hussein, W P Petros, M Ross, et al.
Cancer|April 16, 2026
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617Margo B Gerke, Angelo Marra, Yuan Liu, et al.
Nature Reviews. Cancer|May 12, 2019
Going to extremes: determinants of extraordinary response and survival in patients with cancerFlurina A M Saner, Alan Herschtal, Brad H Nelson, et al.
Pageof 69

Showing results (451-460 of 683) with videos related to

Sort By:
Pageof 69
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 29, 2020
Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinomaKathryn Lasseter, Amin H Nassar, Lana Hamieh, et al.
Journal of Women'S Health (2002)|February 18, 2016
The Association Between Body Mass Index and Presenting Symptoms in African American Women with Ovarian CancerChioma O Erondu, Anthony J Alberg, Elisa V Bandera, et al.
Molecular Carcinogenesis|April 12, 2011
Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer riskEllen L Goode, Kristin L White, Robert A Vierkant, et al.
Nature Genetics|April 26, 2022
HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancerXiaodong Lu, Ka-Wing Fong, Galina Gritsina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcomeAndrew Berchuck, Edwin S Iversen, Jingqin Luo, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
A chromatin fiber model explains cell-free DNA fragmentation signatures of active regulatory elementsAlexis Yang, Garyoung Gary Lee, Surya Chhetri, et al.
Gynecologic Oncology|April 17, 2019
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapiesStéphanie L Gaillard, Kaitlyn J Andreano, Laurie M Gay, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignanciesA M Hussein, W P Petros, M Ross, et al.
Cancer|April 16, 2026
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617Margo B Gerke, Angelo Marra, Yuan Liu, et al.
Nature Reviews. Cancer|May 12, 2019
Going to extremes: determinants of extraordinary response and survival in patients with cancerFlurina A M Saner, Alan Herschtal, Brad H Nelson, et al.
Pageof 69